The Cause of Alzheimer's Might Be Coming From Within Your Mouth
While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think.
One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease.
Watch the video below for a summary of their study:
In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients.
It wasn't the first time the two factors have been linked, but the researchers went further.
In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's.
The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation.
But it was clear they thought we had a strong line of investigation here.
P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme)
"Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time.
"Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis."
In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin.
But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's.
That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care.
The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer.
"Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper.
Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation.
We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic.
"Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement.
The findings were reported in Science Advances.
An earlier version of this story was published in January 2019.
Common Diabetes Drug Linked to 'Exceptional Longevity' in Women
Increased Toxicity Risk Identified For Children With ADHD, Autism
Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is actively leveraging artificial intelligence (AI) to revolutionize the delivery of healthcare, aiming to make it more personalized, scalable, and accessible. The company has strategically invested in expanding its AI capabilities, marked by the appointment of Mo Elshenawy — former president and chief technology officer (CTO) at Cruise and an AI expert — as its CTO in May. Elshenawy's expertise is expected to drive the development of an AI-powered healthcare platform that integrates diagnosis, treatment and delivery into a seamless and individualized experience. He emphasized that Hims & Hers is uniquely positioned to lead a healthcare transformation by using AI and data to deliver care that is smarter, more adaptive and deeply attuned to each patient's needs. To support this transformation, Hims & Hers recently raised $870 million in convertible notes in May, a portion of which is earmarked to advance AI tools, expand the company's data pipeline and enhance personalized treatments. This funding reflects HIMS' intention to modernize healthcare infrastructure using AI, not only to improve diagnostic accuracy but also to create a more intuitive and efficient patient journey. Their existing initiatives, such as the intelligent MedMatch routing system and efforts to deepen technological personalization, illustrate a clear roadmap for integrating AI into core operational processes. These developments position Hims & Hers at the forefront of AI-enabled healthcare delivery. Teladoc Health, Inc. TDOC is harnessing AI to strengthen its virtual care ecosystem, enhance diagnostics and personalize care delivery. Teladoc Health integrates AI across clinical workflows, using it for intelligent triage, patient engagement and predictive analytics to improve outcomes and operational efficiency. TDOC continues to scale its AI capabilities to support complex chronic condition management and behavioral health services. Through these innovations, Teladoc Health positions itself as a leading digital health provider, leveraging AI to expand access and elevate patient experiences. Tempus AI, Inc. TEM is deeply embedding AI across its precision medicine operations, using its proprietary AI platform, Lens, to analyze multimodal healthcare data. Tempus AI drives innovation in oncology and neurogenomics, notably through a collaboration with Northwestern University's Abrams Research Center to apply AI in Alzheimer's research. TEM also integrates AI into its diagnostics and data services, enabling real-time clinical decision support. Through this approach, Tempus AI is transforming healthcare by advancing targeted therapies, optimizing clinical workflows and scaling personalized treatment models. Shares of Hims & Hers have gained 95.7% year to date compared with the industry's growth of 19.7%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 4.1X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of C. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 174.1% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
a day ago
- Miami Herald
Trump's science cuts are great news — for other countries
Of all the questionable things President Trump has done recently — such as starting trade wars with traditional U.S. allies, threatening to invade friendly countries and pushing for bills that would balloon the U.S. deficit — one of the most important, yet least discussed, is his defunding of U.S. science programs. Since the start of his second term on Jan. 20, Trump has set in motion the most sweeping cuts to scientific research in modern U.S. history, including public grants for research into Alzheimer's, cancer and other major diseases. In addition to cutting research funds for leading U.S. universities, such as Harvard and Princeton, Trump's 2026 budget has led to the planned layoffs of thousands of scientists at some of the world's leading scientific institutions. Many U.S. scientists are now moving to Canada and Europe, where leaders in France and other countries have already opened their doors —and their budgets— to America's scientific refugees. A White House document proposing the 2026 budget calls for a 57% reduction for the U.S. National Science Foundation (NSF), which supports basic research in science and engineering, from $9 billion to $3.9 billion. It also calls for a 40% cut in the funding for the National Institutes of Health (NIH), the world's biggest public funder of biomedical research, from $47 billion to $27 billion. To put these figures in perspective, Trump's 'Big, beautiful bill,' which was close to being passed by Congress at the time of this writing, included $45 billion in new funds to build detention facilities — critics call them 'concentration camps' — for undocumented immigrants. As I have shown in previous columns, most current immigration detainees are not violent criminals, but hard-working people seeking a better life. Already, the NIH has canceled more than 2,400 research projects, the respected journal Nature reported on June 27. Trump's budget cuts to U.S. science are 'unprecedented,' and could have 'catastrophic effects,' Nature said in an earlier report on May. 15. The Trump administration says the NIH, NSF, NASA and other government-funded scientific institutions were rife with waste and politically-motivated 'woke' programs, and needed to be made more efficient. Many grants were awarded under non-scientific diversity, equity and inclusion (DEI) requirements that the Trump administration has now terminated, administration officials say. But most scientists say that, while there's probably some degree of waste in any large organization, Trump's budget cuts are a catastrophic overreaction. The administration is killing research programs that could save millions of lives in America and around the world, as well as crippling U.S. innovation in cutting-edge industries. Rep. Bill Foster, D-Illinois, the only member of Congress with a PhD in physics, told me in an interview that 'Trump is wrecking American science.' He added, 'I understand why you would have to cut things, including science. But this is done in a very sloppy and, frankly, stupid way.' Trump's budget cutters have simply looked for science programs that had the terms 'diversity,' or 'inclusion' somewhere in their paperwork, regardless of their merit, critics say. In many cases, such words were just included pro forma in top-quality scientific research programs. Foster told me he already knows of cases in which professors working on five-year research programs have just learned that their last year of funding is being cut off. They have had to lay off their research teams, leading many scientists to seek jobs abroad. 'Right now, America is bleeding scientific talent,' Foster told me. While much of the U.S. scientific leadership was built thanks to European scientists who moved to America in World War II, such as Nobel laureate Albert Einstein, the reverse trend is taking place now, he added. Indeed, French President Emmanuel Macron and European Commission President Ursula von der Leyen recently announced a $566 million plan at Sorbonne University to lure U.S. science refugees. The program is officially called 'Choose Europe for Science.' In an obvious reference to the United States, Macron said at the announcement ceremony that 'Nobody could imagine a few years ago that one of the great democracies of the world would eliminate research programs on the pretext that the word 'diversity' appeared in its program,' according to a New York Times report. When I asked Foster why he thinks Trump is crippling America's scientific programs, he said, 'I think he's trying to achieve popularity with his base, which comes largely from rural areas.' He added that people living in rural areas may not be fully aware of the benefits of science, and are more likely to blame intellectuals and scientists for the country's problems. Maybe so. But whatever the reason, crippling U.S. science will have dire consequences. America will pay not just in lost discoveries, but in lost lives, lost leadership and a diminished future for generations to come. Don't miss the 'Oppenheimer Presenta' TV show on Sundays at 9 pm E.T. on CNN en Español. Blog:
Yahoo
a day ago
- Yahoo
Dementia warning for rugby players as quarter show red flag signs
A new study suggests former rugby players show a higher prevalence of brain changes linked to dementia than matched members of the general population. Levels of a protein called p-tau217, a potential sign of dementia, were higher overall (17.6 per cent) in a group of 200 retired male and female players who said they had suffered significant previous head impact exposure in their careers, compared to 33 matched controls with no exposure to head injuries. Levels of the protein – common in people with diseases like Alzheimer's – were significantly increased in 46 (23 per cent) of the player group. MRI scans also revealed former players had reduced brain volume in some areas, compared with the control group. None of the participants were found to have dementia at the time of the study, which is ongoing and being conducted by researchers at Imperial College London, University College London and the UK Dementia Research Institute. Dr Jacqui Hanley, head of research at Alzheimer's Research UK, said: 'Although none of the rugby players developed young-onset dementia during the study, they did show changes known to be linked to dementia. READ MORE: Jessie J says she has chosen to stop taking some meds in cancer battle READ MORE: Foster care grandma killed trying to stop boy, 12, taking her car 'These include smaller brain volumes and higher levels of p-tau217 protein in the blood, which is common in people with diseases like Alzheimer's. It is too early to say whether these players will go on to develop dementia and whether the physical brain changes observed will predict cognitive difficulties later in their lives. 'There are also key limitations to bear in mind, such as the reliance on self-reporting and interview to determine traumatic brain injury history. However, as the study continues for another four years it should provide some insight into whether these markers in the blood and brain continue to change and how this could impact the rugby players' memory and thinking abilities.' Previous studies have suggested a link between playing rugby and football and an increased risk of developing neurodegenerative disease, such as the FIELD Study in football, which found footballers were three-and-a-half times more likely to die of neurodegenerative disease than age-matched members of the population. There are ongoing legal cases in rugby league, rugby union and football involving former players who claim the sporting authorities failed to adequately protect them from exposure to head injuries.
